JP2020522260A - 新規抗cd3抗体 - Google Patents
新規抗cd3抗体 Download PDFInfo
- Publication number
- JP2020522260A JP2020522260A JP2019566606A JP2019566606A JP2020522260A JP 2020522260 A JP2020522260 A JP 2020522260A JP 2019566606 A JP2019566606 A JP 2019566606A JP 2019566606 A JP2019566606 A JP 2019566606A JP 2020522260 A JP2020522260 A JP 2020522260A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- functional fragment
- seq
- light chain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 141
- 239000012634 fragment Substances 0.000 claims description 133
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 85
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 78
- 229920001184 polypeptide Polymers 0.000 claims description 66
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 66
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 48
- 150000007523 nucleic acids Chemical group 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 40
- 239000013598 vector Substances 0.000 claims description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 238000004925 denaturation Methods 0.000 claims description 8
- 230000036425 denaturation Effects 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 238000005558 fluorometry Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 abstract description 67
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 abstract description 67
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 abstract description 52
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 abstract description 52
- 238000010586 diagram Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 141
- 235000001014 amino acid Nutrition 0.000 description 51
- 108091007433 antigens Proteins 0.000 description 40
- 102000036639 antigens Human genes 0.000 description 40
- 239000000427 antigen Substances 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 36
- 210000001744 T-lymphocyte Anatomy 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 32
- 102000008100 Human Serum Albumin Human genes 0.000 description 26
- 108091006905 Human Serum Albumin Proteins 0.000 description 26
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 24
- 108091008874 T cell receptors Proteins 0.000 description 23
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 22
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 21
- 230000004913 activation Effects 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 19
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 19
- 125000000539 amino acid group Chemical group 0.000 description 19
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 18
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 18
- 241000282567 Macaca fascicularis Species 0.000 description 18
- 230000006044 T cell activation Effects 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000012636 effector Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 13
- 210000003000 inclusion body Anatomy 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 230000009089 cytolysis Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 210000004602 germ cell Anatomy 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241000282577 Pan troglodytes Species 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 241000288906 Primates Species 0.000 description 8
- 239000012911 assay medium Substances 0.000 description 8
- 238000002784 cytotoxicity assay Methods 0.000 description 8
- 231100000263 cytotoxicity test Toxicity 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 206010057248 Cell death Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 206010042971 T-cell lymphoma Diseases 0.000 description 5
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 4
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 230000009258 tissue cross reactivity Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229960002433 cysteine Drugs 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000003571 reporter gene assay Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- 101000642536 Apis mellifera Venom serine protease 34 Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- -1 IL23R Proteins 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 241000288982 Loris Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000282576 Pan paniscus Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000288935 Platyrrhini Species 0.000 description 2
- 108010001267 Protein Subunits Proteins 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 241000288940 Tarsius Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 2
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 102000051957 human ERBB2 Human genes 0.000 description 2
- 102000057111 human IL23R Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 229940019452 loris Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000007981 phosphate-citrate buffer Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000012910 preclinical development Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000008374 Capirona Species 0.000 description 1
- 241000282692 Catarrhini Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000288988 Galago Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001113903 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Protein P4 Proteins 0.000 description 1
- 241000168913 Haplorrhini Species 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 description 1
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101710195550 Interleukin-23 receptor Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000288904 Lemur Species 0.000 description 1
- 241000288903 Lemuridae Species 0.000 description 1
- 241000168911 Lemuriformes Species 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241001436793 Meru Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000160761 Satyrus Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000966334 Simias Species 0.000 description 1
- 241001272562 Simiiformes Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000168914 Strepsirrhini Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 241000168912 Tarsiiformes Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241001504501 Troglodytes Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101150063325 ab gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940045942 acetone sodium bisulfite Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 239000012560 cell impurity Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000001211 electron capture detection Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical class COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
可変軽鎖であって、ここで前記可変軽鎖が、N末端からC末端に向かって、領域LFW1-LCDR1-LFW2-LCDR2-LFW3-LCDR3-LFW4を含み、ここで各LFWは軽鎖フレームワーク領域を表し、そして各LCDRは軽鎖相補性決定領域を表し、そして前記LCDRは一緒になって、配列番号4に記載のVL配列から得られる対応するLCDRに対して少なくとも90%の配列同一性を示す、可変軽鎖;および
可変重鎖であって、ここで前記可変重鎖が、N末端からC末端に向かって、領域HFW1-HCDR1-HFW2-HCDR2-HFW3-HCDR3-HFW4を含み、ここで各HFWは重鎖フレームワーク領域を表し、そして各HCDRは重鎖相補性決定領域を表し、そして前記HCDRは一緒になって、配列番号8に記載のVH配列から得られる対応するHCDRに対して少なくとも90%の配列同一性を示す、可変重鎖
を含む前記抗体またはその機能的断片に関する。
本開示はヒトCD3に特異的な新規抗体、特にCD3εドメインに特異的な抗体に関する。
(a) 可変軽鎖であって、ここで前記可変軽鎖が、N末端からC末端に向かって、領域LFW1-LCDR1-LFW2-LCDR2-LFW3-LCDR3-LFW4を含み、ここで各LFWは軽鎖フレームワーク領域を表し、そして各LCDRは軽鎖相補性決定領域を表し、そして前記LCDRは一緒になって、配列番号4に記載のVL配列から得られる対応するLCDRに対して少なくとも60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98または99%、好ましくは少なくとも90%の配列同一性を示す、可変軽鎖;および
(b) 可変重鎖であって、ここで前記可変重鎖が、N末端からC末端に向かって、領域HFW1-HCDR1-HFW2-HCDR2-HFW3-HCDR3-HFW4を含み、ここで各HFWは重鎖フレームワーク領域を表し、そして各HCDRは重鎖相補性決定領域を表し、そして前記HCDRは一緒になって、配列番号8に記載のVH配列から得られる対応するHCDRに対して少なくとも60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98または99%、好ましくは少なくとも90%の配列同一性を示す、可変重鎖
を含む前記抗体またはその機能的断片に関する。
(i) 各々配列番号1、2および3のLCDR1、LCDR2およびLCDR3配列;
(ii) ヒトVκフレームワーク領域FW1〜FW3、特にヒトVκ1フレームワーク領域FW1〜FW3;
(iii) FW4であって、(a) FW4のヒトVλ生殖細胞系配列、特に配列番号17と配列番号18から、好ましくは配列番号17から選択されるヒトVλ生殖細胞系配列;および(b) Vλベースの配列であって、配列番号17と配列番号18から、好ましくは配列番号17から選択されるアミノ酸配列を含むFW4の最も近いヒトVλ生殖細胞系配列と比較して、1つまたは2つの突然変異、特に1つの突然変異を有するVλベースの配列、から選択されるFW4。
(i) 特に表面プラズモン共鳴により測定した時、より特に実施例2.1に記載の方法により決定した時、40 nM未満、特に10 nM未満、より特に6 nM未満のヒトCD3への結合のKD値;
(ii) 特に表面プラズモン共鳴により測定した時、より特に実施例2.1に記載の方法により決定した時、20 nM未満、特に10 nM未満、より特に5 nM未満のカニクイザルCD3への結合のKD値;および
(iii)以前に記載された(Egan他、MAbs, 9(1) (2017), 68-84;Niesen他、Nature Protocols, 2(9) (2007) 2212-2221)示差走査蛍光分析法(DSF)により測定した時、特にサンプルを0.15-0.25 M NaCl、特に0.15 M NaClを含む3.5〜7.5の範囲のpH値を有する5つのリン酸−クエン酸緩衝液中に希釈した時、scFv抗体フォーマットで発現させた場合に、少なくとも60℃、特に少なくとも65℃、より特に少なくとも68℃を超える熱変性温度(Tm)の平均中点。scFv構築物の熱変性の遷移の中間点は、蛍光色素SYPRO(登録商標)Orangeを使用した示差走査蛍光分析によって決定される(Wong & Raleigh, Protein Science 25 (2016) 1834-1840参照)。関連する賦形剤条件中のサンプルは、関連の緩衝液中に調製した原液賦形剤中にスパイクすることにより、50μg/mlの最終タンパク質濃度で調製する。緩衝液スカウティング実験では、総量100μLの5×SYPRO(登録商標)Orangeの最終濃度を含む、異なるpH値(pH 3.4, 4.4, 5.4, 6.4および7.2)を有する最終scFv緩衝液中にサンプルを希釈する。未知のサンプルと共に、scFv DSF参照を内部標準として測定する。25μLの調製サンプルを、3連で白色のAB遺伝子PCRプレートに添加する。アッセイはサーマルサイクラーとして使用されるqPCR装置上で実行され、蛍光発光はソフトウェアのカスタム色素較正ルーチン分析を使用して検出される。試験サンプルを含むPCRプレートは、25℃から1℃刻みで96℃までの温度勾配にかけられ、各昇温後に30秒の休止を含む。総アッセイ時間は約2時間である。Tmは、曲線の変曲点を計算するために数学的二次導関数を使用し、ソフトウェアGraphPad Prismによって計算される。報告されたTmは、3回の測定値の平均である。特定の実施形態において、Tmの測定は実施例2.2に記載のように実施され、サンプルは0.25 M NaClを含有するpH 6.4のリン酸−クエン酸緩衝液で希釈される。
CD3ε結合ドメインのリード候補の創出のために、6つのウサギモノクローナル抗体クローンを選択した。
2.1 ヒトおよびカニクイザルCD3εに対する親和性
ヒト化scFvのヒトおよびカニクイザルCD3εに対する親和性は、T200装置(Biacore、General Electric社製)を使用したSPR測定により決定した。アミンカップリング化学を使用して、CD3εをCM5センサーチップ(Biacore、General Electric社製)に直接結合した。再生探索と表面性能試験を実行して最適アッセイ条件を見出した後、scFv用量応答を測定し、得られた結合曲線を二重参照(空の参照チャネルとゼロの分析対象注入)し、1:1 ラングミュア(Langmuir)モデルを使用して動態パラメーターを読み取った。アッセイは、pH 7.4の1×PBS-Tweenバッファー中で行った。
試験したscFv構築物の熱変性の推移の中点を、本質的にNiesenにより記載された通りに(Niesen他、Nat Protoc. 2 (2007) 2212-21)、示差走査蛍光測定法(DSF)により決定した。DSFアッセイはqPCR機器(例えばMX3005p、Agilent Technologies製)で実行される。サンプルは、総容量25μLにおいて最終濃度5×SYPROオレンジを含むバッファー(クエン酸−リン酸 pH 6.4、0.25 M NaCl)中に希釈した。バッファー探索(スカウティング)実験において、変性温度のpH依存性が決定され、全ての構築物について同等のpH特性が観察された。サンプルは同じものを3通り作製して測定し、25〜96℃の温度勾配をプログラムした。蛍光シグナルを取得し、生データをGraphPad Prism(GraphPad Software Inc.)で分析した。
各サンプルの初期モノマー含有量(d0)は、サイズ排除高速液体クロマトグラフィー(SE-HPLC)によって決定した。ランニングバッファー(250 mM NaCl、50 mM NaOAc、pH 6.0; 0.35 mL/分の流速)を用いて、サンプルをShodexTM(昭和電工製)KW402.5-4Fカラムに通過させた。溶出したタンパク質を280 nmでの吸光度により検出した。モノマータンパク質の割合を計算するために、モノマーの保持時間の所でピークに達する曲線下の面積を、サンプルマトリックスに起因しない曲線下総面積により除算した。サンプルを4℃で保存し、10 mg/mLの濃度で28日間に渡って繰り返し分析した(図1)。
CD3ドメインの機能的特徴付けのため、T細胞活性化と標的細胞枯渇を誘発する可能性のあるドメインを試験するために、特定のドメインを一本鎖ダイアボディフォーマットに組み込んだ。
4.1 NFATレポーター遺伝子アッセイによるT細胞活性化
T細胞活性化はNFATアッセイにおいて試験した。Jurkat NFATレポーターT細胞株は、IL-2プロモーターからのNFAT(活性化T細胞の核因子)応答要素の制御下でルシフェラーゼレポーター遺伝子を発現する(GloResponseTM(商標)NFAT-luc2 Jurkat Cells)。転写因子NFATはCD3εの架橋形成によって活性化され、T細胞活性化に関与する多数の遺伝子を誘導する。このシステムでは、CD3εの架橋形成がルシフェラーゼレポーター遺伝子の発現を誘導する。トランスジェニックIL-23R(図2〜7)またはHER2(図8〜9)を発現するチャイニーズハムスター卵巣(CHO-K1)細胞を標的細胞として使用し、親CHO-K1細胞株をネガティブコントロール(陰性対照)細胞株として使用した。50μLのアッセイ培地(RPMI 1640、10%FCS)で希釈した25,000個の生存可能標的細胞を、白色の平底96ウェルプレートに播種した。次に、アッセイ培地で希釈した4倍濃縮試験タンパク質25μLを適切なウェルに添加した。最後に、50,000個のJurkat細胞を含む25μLのアッセイ培地を各ウェルに加え、最初に室温で10分間プレートを穏やかに撹拌しながらインキュベートし、次に37℃、5%CO2に5時間移した。ルシフェラーゼ活性を検出するために、製造業者の指示に従って、ワンステップ・ルシフェラーゼアッセイキット(Amsbio)を使用した。手短に言えば、インキュベーション時間の終わりに、ルシフェラーゼ試薬基質をルシフェラーゼ試薬緩衝液と混合し、50μLを各ウェルに加え、プレートを室温で遮光下で15分間インキュベートした。プレートは、Flexstation IIIマルチモード・マイクロプレートリーダー(Molecular Devices)を使って読み取った。
血球分画:
末梢血単核細胞(PBMC)は、製造元の教示に従ってリンパ球分離培地Lymphoprep(Stemcell technologies製)を使用して、健常ボランティアまたは健常カニクイザルの新鮮血液から単離された。簡単に説明すると、血液をヒトPBMC単離バッファー(PBS、2%FCS、2 mM EDTA)またはカニクイザルPBMCs分離バッファー(PBS、5%FCS、2 mM EDTA)で1:2に希釈し、推奨量のLymphoprep培地を含むLeucoSepチューブ中に投入した。LeucoSepチューブは、ブレーキを使用せずに、RTで800×g(ヒト血液)または2,000×g(カニクイザル血液)にて30分間遠心分離した。次に、PBMCを含む細胞層を回収し、ヒトまたはカニクイザルのPBMC単離バッファーで2回洗浄し、赤血球溶解バッファーを使用して室温で5分間赤血球を溶解させた。次いで、単離されたヒト細胞およびカニクイザル細胞を、それぞれの単離用バッファーで1回およびアッセイ培地(RPMI-1640、10%FCS)で1回洗浄した。血小板除去後、単離されたPBMCは、1 mLあたり3×106個の生存細胞の密度でアッセイ培地に再懸濁した。
抗IL23RxCD3ε二重特異性構築物については、トランスジェニックIL-23R発現チャイニーズハムスター卵巣(CHO-K1)細胞を標的細胞として使用し、親CHO-K1細胞株をネガティブコントロール(陰性対照)細胞株として使用した(図2〜7)。抗HER2x抗CD3ε二重特異性構築物には、トランスジェニックHER2を発現するチャイニーズハムスター卵巣(CHO-K1)細胞を使用した(図8〜9)。予めPKH67で標識され、75μLのアッセイ培地(RPMI-1640、10%FCS)中に希釈した5,000個の生存可能標的細胞を96ウェルプレートに添加した。次に、アッセイ培地で希釈した6倍濃縮の試験タンパク質25μLを適当なウェルに添加した。次に、E:T比が30:1になるように、50μLのアッセイ培地中に希釈した150,000個の生存可能エフェクター細胞(PBMC)を各ウェルに加え、RTで転倒ミキサー上でプレートを混合した後、37℃で5%CO2でインキュベートした。16時間後、細胞をトリプシン処理し、染色バッファー(PBS、2%BCS、2 mM EDTA)中に再懸濁し、非結合プレートに移した。
標的細胞の特異的溶解[%]=[1−(サンプルの標的細胞生存率)/(対照サンプルの平均生存率)] × 100
T細胞活性化の特異性の比較
PRO389(IL23RxCD31st gen Numab)およびPRO460(IL23RxCD3I2C Amgen)によって媒介される標的発現細胞の特異的標的細胞溶解の比較は、それぞれ5.3および3.3 pMのEC50で同様の効力を示す(図2参照)。また、達成可能な最大溶解レベルは、これら2つのタンパク質で同一である。しかしながら、抗原陰性細胞との組み合わせでは、PRO460(IL23RxCD32nd gen Numab)がネガティブコントロール(陰性対照)細胞の部分的枯渇を引き起こすような高濃度の分子の所では違いが現れる(図2)。フローサイトメトリー(FC)による細胞毒性アッセイのウェルでのエフェクター細胞活性化の定量は、特異的溶解の結果と一致する。標的陽性細胞を含む条件の場合、エフェクター細胞の活性化に対する用量応答も観察される。これらの結果は、エフェクター細胞活性化について同様のEC50を示すが、PRO389(IL23RxCD31st gen Numab)は、見かけ上、より低い最大応答のプラトー状態に達するようである(図3参照)。標的陰性細胞を含むウェルでは、非特異的活性化のEC50の明らかな違いが見られ、2分子間を識別する。高濃度の両分子を投与すると、標的が存在しない場合でも活性化された細胞が増加する(図3)。しかし、この効果は約25倍低い濃度の分子PRO460(IL23RxCD3I2C Amgen)において観察される。従って、データは、PRO389の抗CD3ドメイン(IL23RxCD31st gen Numab)が、同じフォーマットと標的結合ドメインを使用したPRO460の抗CD3ドメイン(IL23RxCD3I2C Amgen)との直接比較において、より特異的なT細胞活性化を示すという証拠を提供する。
抗CD3ε結合ドメインI2Cの重要な特徴(米国特許2010/0150918)は、ヒトと非チンパンジー霊長類に対する異種間反応性であり、誘導治療薬の前臨床開発において利点を提供する。PRO624(IL23RxCD32nd gen Numab)およびPRO389(IL23RxCD31st gen Numab)中に組み込まれた抗CD3εドメインは両方とも、SPR測定で組換えヒトおよびカニクイザルCD3εに結合する(表3およびWO 2014/191113)。しかしながら、PRO389(IL23RxCD31st gen Numab)に組み込まれているクローン09-24-H09のドメインの反応性は、細胞膜結合型CD3εの細胞環境では維持されなかった。対照的に、PRO624(IL23RxCD32nd gen Numab)に存在するクローン28-21-D09に由来するドメインは、細胞アッセイでも保存された種反応性を示す。このような異なる特徴は、カニクイザルPBMCをエフェクター細胞として使用した細胞毒性アッセイにより特徴付けられた。
Claims (15)
- ヒトCD3に特異的である抗体またはその機能的断片であって、
(a) 可変軽鎖であって、
ここで前記可変軽鎖が、N末端からC末端に向かって、領域LFW1-LCDR1-LFW2-LCDR2-LFW3-LCDR3-LFW4を含み、ここで各LFWは軽鎖フレームワーク領域を表し、そして各LCDRは軽鎖相補性決定領域を表し、そして前記LCDR1は配列番号1に記載の通りであり、前記LCDR2は配列番号2に記載の通りであり、そして前記LCDR3は配列番号3に記載の通りである、可変軽鎖;および
(b) 可変重鎖であって、
ここで前記可変重鎖が、N末端からC末端に向かって、領域HFW1-HCDR1-HFW2-HCDR2-HFW3-HCDR3-HFW4を含み、ここで各HFWは重鎖フレームワーク領域を表し、そして各HCDRは重鎖相補性決定領域を表し、そして前記HCDR1は配列番号5に記載の通りであり、前記HCDR2は配列番号6に記載の通りであり、そして前記HCDR3は配列番号7に記載の通りである、可変重鎖
を含む、抗体またはその機能的断片。 - 前記可変軽鎖がVκ1軽鎖であり、および/または前記可変重鎖がVH3である、請求項1に記載の抗体またはその機能的断片。
- 前記可変軽鎖が配列番号4のアミノ酸配列に対して少なくとも90%の配列同一性を示し、および/または前記可変重鎖が配列番号8のアミノ酸配列に対して少なくとも90%の配列同一性を示す、請求項1または請求項2に記載の抗体またはその機能的断片。
- 前記可変軽鎖がAHo番号付け法によると軽鎖のアミノ酸位置54位にアルギニンまたはリジン、好ましくはアルギニンを含む、請求項1〜3のいずれか一項に記載の抗体またはその機能的断片。
- 前記可変軽鎖が配列番号4のアミノ酸配列を含み、そして前記可変重鎖が配列番号8のアミノ酸配列を含む、請求項3〜4のいずれか一項に記載の抗体またはその機能的断片。
- 前記抗体またはその機能的断片が、次のパラメータ:
(i) 特に表面プラズモン共鳴により決定した時に、40 nM未満、特に10 nM未満、より特に6 nM未満のヒトCD3への結合のKD値;
(ii) 特に表面プラズモン共鳴により決定した時に、20 nM未満、特に10 nM未満、より特に5 nM未満のカニクイザルCD3への結合のKD値;および
(iii)特に示差走査蛍光分析法(DSF)により測定した時、scFv抗体フォーマットで発現させた場合、少なくとも60℃、特に少なくとも65℃、より特に少なくとも68℃を超える熱変性温度(Tm)の平均中点
の1つまたは複数により特徴付られる、請求項1〜5のいずれか一項に記載の抗体またはその機能的断片。 - 請求項1〜6のいずれか一項に記載の抗体またはその機能的断片を含む多重特異性ポリペプチド。
- 請求項1〜6のいずれか一項に記載の抗体もしくはその機能的断片または請求項7の多重特異性ポリペプチドと、薬学的に許容される担体および/または賦形剤とを含む、医薬組成物。
- 医薬として用いるための、請求項1〜6のいずれか一項に記載の抗体もしくはその機能的断片、請求項7の多重特異性ポリペプチド、または請求項8の組成物。
- 医薬の製造における、請求項1〜6のいずれか一項に記載の抗体もしくはその機能的断片、請求項7の多重特異性ポリペプチド、または請求項8の組成物の使用。
- 請求項1〜6のいずれか一項に記載の抗体またはその機能的断片をコードする核酸配列または核酸配列の集合体。
- 請求項11の核酸配列または核酸配列の集合体を含む、ベクターまたはベクターの集合体。
- 請求項1〜6のいずれか一項に記載の抗体またはその機能的断片を生産する方法であって、請求項11の核酸配列もしくは核酸配列の集合体、または請求項12のベクターもしくはベクターの集合体を発現させることを含む方法。
- 多重特異性構築物の作製方法であって、
(a) 1もしくは複数のステップにおいて、請求項1〜6のいずれか一項に記載の抗体またはその機能的断片をコードする1または複数の核酸配列を、少なくとも第二の結合ドメインまたはその断片をコードする核酸配列と、随意に1または複数の追加の結合ドメインまたはその断片をコードする核酸配列とを含む多重特異性構築物へクローニングすること
を含む方法。 - 前記第二の結合ドメインが第二の抗体またはその機能的断片である、請求項14に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762515293P | 2017-06-05 | 2017-06-05 | |
US62/515,293 | 2017-06-05 | ||
EP17203832 | 2017-11-27 | ||
EP17203832.5 | 2017-11-27 | ||
PCT/EP2018/064630 WO2018224441A1 (en) | 2017-06-05 | 2018-06-04 | Novel anti-cd3 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020522260A true JP2020522260A (ja) | 2020-07-30 |
JP7247110B2 JP7247110B2 (ja) | 2023-03-28 |
Family
ID=62555064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019566606A Active JP7247110B2 (ja) | 2017-06-05 | 2018-06-04 | 新規抗cd3抗体 |
Country Status (9)
Country | Link |
---|---|
US (2) | US11319371B2 (ja) |
EP (1) | EP3634998A1 (ja) |
JP (1) | JP7247110B2 (ja) |
KR (1) | KR102651965B1 (ja) |
CN (1) | CN110691789A (ja) |
AU (1) | AU2018280681A1 (ja) |
CA (1) | CA3064163A1 (ja) |
IL (1) | IL271128B1 (ja) |
MA (1) | MA49250A (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL271128B1 (en) * | 2017-06-05 | 2024-06-01 | Numab Therapeutics AG | New anti-3CD antibodies |
AU2022341443A1 (en) * | 2021-09-13 | 2024-03-28 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-human cd3 antibody and use thereof |
EP4416182A1 (en) * | 2021-10-12 | 2024-08-21 | Concept to Medicine Biotech Co., Ltd. | Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins |
WO2023169419A1 (en) * | 2022-03-09 | 2023-09-14 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-cd3 antibodies and uses thereof |
CN115286715B (zh) * | 2022-05-18 | 2023-05-23 | 上海百英生物科技股份有限公司 | 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法 |
CN116284391B (zh) * | 2022-11-16 | 2023-08-08 | 艾可泰科(浙江)控股有限公司 | 使用胰岛干细胞和抗体治疗糖尿病 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015063339A1 (en) * | 2013-11-04 | 2015-05-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
WO2016020444A1 (en) * | 2014-08-07 | 2016-02-11 | Affimed Gmbh | Cd3 binding domain |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0919840B1 (pt) | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
EP3149041A1 (en) | 2014-05-28 | 2017-04-05 | F. Hoffmann-La Roche AG | Antibodies binding to human and cynomolgus cd3 epsilon |
MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
WO2016184570A1 (en) | 2015-05-18 | 2016-11-24 | Numab Ag | Novel treatment methods based on multifunctional molecules |
JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
IL271128B1 (en) * | 2017-06-05 | 2024-06-01 | Numab Therapeutics AG | New anti-3CD antibodies |
CN110719918B (zh) * | 2017-06-05 | 2024-05-24 | 努玛治疗有限公司 | 靶向至少cd3和hsa的异源二聚体多特异性抗体形式 |
EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
EP3915580A1 (en) * | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Multispecific antibody |
IL298076A (en) * | 2020-05-29 | 2023-01-01 | Numab Therapeutics AG | Multispecific antibodies |
-
2018
- 2018-06-04 IL IL271128A patent/IL271128B1/en unknown
- 2018-06-04 US US16/619,121 patent/US11319371B2/en active Active
- 2018-06-04 CA CA3064163A patent/CA3064163A1/en active Pending
- 2018-06-04 KR KR1020197035542A patent/KR102651965B1/ko active IP Right Grant
- 2018-06-04 MA MA049250A patent/MA49250A/fr unknown
- 2018-06-04 JP JP2019566606A patent/JP7247110B2/ja active Active
- 2018-06-04 EP EP18729644.7A patent/EP3634998A1/en active Pending
- 2018-06-04 AU AU2018280681A patent/AU2018280681A1/en active Pending
- 2018-06-04 CN CN201880036701.7A patent/CN110691789A/zh active Pending
-
2022
- 2022-04-22 US US17/727,449 patent/US20220403028A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015063339A1 (en) * | 2013-11-04 | 2015-05-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
WO2016020444A1 (en) * | 2014-08-07 | 2016-02-11 | Affimed Gmbh | Cd3 binding domain |
Also Published As
Publication number | Publication date |
---|---|
JP7247110B2 (ja) | 2023-03-28 |
US20200115449A1 (en) | 2020-04-16 |
IL271128B1 (en) | 2024-06-01 |
US20220403028A1 (en) | 2022-12-22 |
KR20200013233A (ko) | 2020-02-06 |
AU2018280681A1 (en) | 2019-12-05 |
KR102651965B1 (ko) | 2024-03-28 |
CN110691789A (zh) | 2020-01-14 |
CA3064163A1 (en) | 2018-12-13 |
US11319371B2 (en) | 2022-05-03 |
IL271128A (en) | 2020-01-30 |
MA49250A (fr) | 2021-04-14 |
EP3634998A1 (en) | 2020-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7247110B2 (ja) | 新規抗cd3抗体 | |
JP2020535799A (ja) | 新規の安定した抗体の可変領域フレームワークの組み合わせ | |
CN113880952A (zh) | 自然杀伤细胞接合抗体融合构建体 | |
JP2024036342A (ja) | Cd3を標的とする抗体、二重特異性抗体及びその使用 | |
JP2018501297A (ja) | Cd3/cd38 t細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法 | |
JP2017521998A (ja) | 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法 | |
WO2018224441A1 (en) | Novel anti-cd3 antibodies | |
EP2994490A1 (en) | Bispecific constructs and their use in the treatment of various diseases | |
WO2018224439A1 (en) | Novel anti-hsa antibodies | |
CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
WO2022218380A1 (zh) | 靶向bcma的多特异性抗体 | |
WO2023161457A1 (en) | Bispecific antibodies against cd277 and a tumor-antigen | |
JP2024530451A (ja) | 抗pvrig/抗tigit二重特異性抗体及び応用 | |
JP7130678B2 (ja) | 新規抗hsa抗体 | |
JP2021501569A (ja) | Pdl1を標的とする抗体及びそれを用いる方法 | |
TW202317639A (zh) | 抗人cd3抗體及其應用 | |
JP2023539453A (ja) | Bcmaと結合する単一可変ドメイン及び抗原結合分子 | |
WO2024094151A1 (en) | Multi-specific antibody and medical use thereof | |
WO2024094017A1 (zh) | 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用 | |
CN117940460A (zh) | 双特异性抗原结合分子及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220524 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230214 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7247110 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |